Formation Bio, an AI-native pharma company focused on accelerating drug development, today announced that its subsidiary Libertas Bio has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to ...

Having secured one of last year’s largest funding rounds, Formation Bio is eyeing up to 545 million euros from a licensing deal with Sanofi.

The AI in Life Science Market is anticipated to experience a remarkable compound annual growth rate (CAGR) of around 25% in ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...

Sanofi buys a drug from Dren Bio to claim a stake in the emerging field of deep B-cell depletion for autoimmune diseases.

Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a 21-valent shot licensed from SK Biosciences into phase 3 testing.

DoH and Sanofi strengthen health collaboration The collaboration will leverage Abu Dhabi’s health-tech ecosystem and advanced research infrastructure and Sanofi’s research and development expertise.

MONROE COUNTY, Pa. - Sanofi, maker of anti-inflammation drug Dupixent, will report third-quarter earnings Friday before the opening of U.S. markets. Paris-based Sanofi is the parent company of ...